UCSF School of Medicine

Nathan Kuppermann, M.D., M.P.H., named chief academic officer and chair of Pediatrics at Children’s National Hospital

Retrieved on: 
Wednesday, March 13, 2024
JAMA, Research, Health care, Health, Public, Public health, EVP, UCSF School of Medicine, Pediatric Research, Education, UC, Global Health, Emergency medicine, Society, Publication, Emergency medical services, Hospital, Children's National Hospital, Stanford University, National academy, MHA, Pediatrics, BMJ

Washington, D.C., March 13, 2024 (GLOBE NEWSWIRE) -- Children's National Hospital has appointed Nathan Kuppermann, M.D., M.P.H., as its new executive vice president (EVP), chief academic officer (CAO) and chair of Pediatrics.

Key Points: 
  • Washington, D.C., March 13, 2024 (GLOBE NEWSWIRE) -- Children's National Hospital has appointed Nathan Kuppermann, M.D., M.P.H., as its new executive vice president (EVP), chief academic officer (CAO) and chair of Pediatrics.
  • He comes to Children’s National from UC Davis Health and UC Davis School of Medicine in Sacramento, CA, and will start in September.
  • After a national search, Dr. Kuppermann stood out for his exceptional contributions to clinical and academic research, focusing on pediatric emergency care, and his dedication to mentorship.
  • He completed a pediatrics residency and chief residency at Harbor-UCLA Medical Center and a fellowship in Pediatric Emergency Medicine at Boston Children's Hospital.

Tigerlily Foundation and Labcorp Launch I AM INCLUDED Framework to Increase Clinical Trial Diversity, Accelerate Delivery of Innovative Cancer Treatments

Retrieved on: 
Thursday, November 16, 2023
UCSF School of Medicine, Health equity, Meharry Medical College, Labcorp, Food, National Cancer Institute, Tigerlily, Morehouse School of Medicine, Disease, Duke Cancer Institute, Clinical trial, Mortality, Breast cancer, NCI, Patient, FDA, Person, Partnership, Pharmaceutical industry, Nursing, University, BURLINGTON

BURLINGTON, N.C. and WASHINGTON, Nov. 16, 2023 /PRNewswire/ -- Today, the Tigerlily Foundation (Tigerlily), a leading breast cancer patient advocacy organization, and Labcorp , a global leader of innovative and comprehensive laboratory services, announced the launch of I AM INCLUDED , a co-developed, modernized, multi-stakeholder framework for sharing best practices of U.S. diverse clinical trial site leaders for inclusive cancer clinical trials.

Key Points: 
  • BURLINGTON, N.C. and WASHINGTON, Nov. 16, 2023 /PRNewswire/ -- Today, the Tigerlily Foundation (Tigerlily), a leading breast cancer patient advocacy organization, and Labcorp , a global leader of innovative and comprehensive laboratory services, announced the launch of I AM INCLUDED , a co-developed, modernized, multi-stakeholder framework for sharing best practices of U.S. diverse clinical trial site leaders for inclusive cancer clinical trials.
  • Labcorp and Tigerlily then jointly hosted Patient Listening and Clinical Site Listening Summits to discuss health equity and diversity in cancer clinical trials.
  • Following the listening summits, I AM INCLUDED was developed as a transformational, actionable framework to provide proven and successful actions and serve as a guide for clinical trial site leaders to diversify enrollment in clinical research.
  • "Partnership without action is just admiring the problem," said Maimah Karmo, founder and CEO, Tigerlily Foundation.

Apple Tree Partners Recruits Noted Biotech Entrepreneur and Computer-Aided Drug Design Pioneer Matthew P. Jacobson, Ph.D., as New Venture Partner

Retrieved on: 
Tuesday, July 11, 2023
Columbia University, UCSF School of Pharmacy, University of Oxford, PLOS Computational Biology, University, Therapy, Education, Emeritus, NSF, National Science Foundation, ATP, Stanford University, Partner (business rank), Research, MIT, Science, Biochemistry, UCSF School of Medicine, Structure, Entrepreneurship, Parkinson's disease, Publication, Investment, UCSF, Medicinal chemistry, Chemistry, Sickle cell disease, Knowledge, USCF, Ecosystem, FDA, ALS, Jacobson, Graduate Group in the Art and Archaeology of the Mediterranean World, Pfizer, Pharmaceutical industry, Biophysics

NEW YORK and SOUTH SAN FRANCISCO, Calif., July 11, 2023 /PRNewswire/ -- Apple Tree Partners (ATP), a leader in life sciences venture capital, announced today that Matthew P. Jacobson, Ph.D., serial biotech entrepreneur and Professor Emeritus in the Department of Pharmaceutical Chemistry at University of California San Francisco (UCSF), has joined ATP as a venture partner. In this role, he will identify opportunities for new life sciences investments and company creation and provide strategic expertise to ATP's portfolio companies. He will be based in ATP's South San Francisco office.

Key Points: 
  • In this role, he will identify opportunities for new life sciences investments and company creation and provide strategic expertise to ATP's portfolio companies.
  • Dr. Jacobson's research interests are in the areas of computational biophysics and computer-aided drug design; he is the author of more than 200 publications and several patents.
  • He presently devotes most of his time to biotech entrepreneurship and has co-founded six successful biotech companies in the past dozen years.
  • "We have enjoyed a productive working relationship with Matt for several years, and we are delighted to formally welcome him to ATP as a venture partner and scientific advisor," said Seth Harrison, M.D., Apple Tree Partners' founder and Managing Partner.

Apple Tree Partners Recruits Noted Biotech Entrepreneur and Computer-Aided Drug Design Pioneer Matthew P. Jacobson, Ph.D., as New Venture Partner

Retrieved on: 
Tuesday, July 11, 2023
Columbia University, UCSF School of Pharmacy, University of Oxford, PLOS Computational Biology, University, Therapy, Emeritus, Education, NSF, National Science Foundation, ATP, Stanford University, Partner (business rank), Research, MIT, Science, Biochemistry, UCSF School of Medicine, Structure, Entrepreneurship, Parkinson's disease, Publication, Investment, UCSF, Medicinal chemistry, Chemistry, Sickle cell disease, Knowledge, USCF, Ecosystem, FDA, ALS, Jacobson, Graduate Group in the Art and Archaeology of the Mediterranean World, Pfizer, Pharmaceutical industry, Biophysics

NEW YORK and SOUTH SAN FRANCISCO, Calif., July 11, 2023 /PRNewswire/ -- Apple Tree Partners (ATP), a leader in life sciences venture capital, announced today that Matthew P. Jacobson, Ph.D., serial biotech entrepreneur and Professor Emeritus in the Department of Pharmaceutical Chemistry at University of California San Francisco (UCSF), has joined ATP as a venture partner. In this role, he will identify opportunities for new life sciences investments and company creation and provide strategic expertise to ATP's portfolio companies. He will be based in ATP's South San Francisco office.

Key Points: 
  • In this role, he will identify opportunities for new life sciences investments and company creation and provide strategic expertise to ATP's portfolio companies.
  • Dr. Jacobson's research interests are in the areas of computational biophysics and computer-aided drug design; he is the author of more than 200 publications and several patents.
  • He presently devotes most of his time to biotech entrepreneurship and has co-founded six successful biotech companies in the past dozen years.
  • "We have enjoyed a productive working relationship with Matt for several years, and we are delighted to formally welcome him to ATP as a venture partner and scientific advisor," said Seth Harrison, M.D., Apple Tree Partners' founder and Managing Partner.

LIXTE BIOTECHNOLOGY HOLDINGS REPORTS NEWLY PUBLISHED INDEPENDENT PRE-CLINICAL RESEARCH

Retrieved on: 
Tuesday, February 14, 2023
WHEN, Journal, Immunotherapy, Animal, Assistant, Journal of Clinical Investigation, RESEARCH, UCSF School of Medicine, PP2A, Neurology, Cancer, Pharmaceutical industry

PASADENA, CA, Feb. 14, 2023 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT) announced that, as recently reported in The Journal of Clinical Investigation, PP2A, the pharmacologic target of LIXTE’s lead clinical compound, LB-100, when deficient, enhances the effects of immune checkpoint blockade of cancer in a mouse model by a previously unappreciated mechanism.

Key Points: 
  • THE RESEARCH SHOWS THAT PP2A, THE TARGET OF LIXTE’S LEAD CLINICAL COMPOUND, LB-100, WHEN DEFICIENT, ENHANCES EFFECTS OF IMMUNE CHECKPOINT BLOCKADE OF CANCER BY A PREVIOUSLY UNAPPRECIATED MECHANISM
    PASADENA, CA, Feb. 14, 2023 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc .
  • (“LIXTE” or the “Company”) ( Nasdaq: LIXT ) announced that, as recently reported in The Journal of Clinical Investigation, PP2A, the pharmacologic target of LIXTE’s lead clinical compound, LB-100, when deficient, enhances the effects of immune checkpoint blockade of cancer in a mouse model by a previously unappreciated mechanism.
  • John S. Kovach, M.D., CEO and Founder of LIXTE, said, “This paper lends additional support to the potential immunotherapy application of LB-100 in cancer treatment.
  • Studies in animals show that low doses of LB-100 enhance the effectiveness of immunotherapy against a variety of cancer types by several mechanisms ( Ho et al., Nature Comm 2018 ; Yen et al.

eFFECTOR Therapeutics Doses First Patient in Second Cohort of Phase 1b Clinical Trial of Zotatifin for the Treatment of COVID-19

Retrieved on: 
Wednesday, September 14, 2022
Hospital, Receptor tyrosine kinase, Plasma, EIF4E, Safety, Stri Parva, COVID-19, UCSF School of Pharmacy, University of California, San Francisco, Effector, RNA transfection, Orthornavirae, Virus, NSCLC, EIF4A, QBI, Severe acute respiratory syndrome coronavirus 2, DARPA, Review, Private Securities Litigation Reform Act, Therapy, COVID, U.S. Securities and Exchange Commission, STRI, Government, ER, Patient, Test, University of California, Cancer, Survival, Disease, Clinical trial, UCSF School of Medicine, Protein, Biology, Solution, NASDAQ, SAN, KRAS, RNA, MNK, Research, Security (finance), GLOBE, Escape Room, Pembrolizumab, University, Genome, CDK, 4F, Pfizer, Death, Pharmaceutical industry, Vaccine, Pharmacy, KICKSTART, Nature

SAN DIEGO and REDWOOD CITY, Calif., Sept. 14, 2022 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (“STRIs”) for the treatment of cancer, today announced it has dosed the first patient in the second cohort of its Phase 1b clinical trial of zotatifin in non-hospitalized adults with confirmed COVID-19 infection. The study is a double-blind, randomized, placebo-controlled trial evaluating the safety and antiviral activity of a single dose of zotatifin and is being conducted in collaboration with the Quantitative Biosciences Institute (QBI) at the University of California, San Francisco, under a $5 million cooperative agreement sponsored by the Defense Advanced Research Projects Agency.

Key Points: 
  • Dose escalation to the second cohort comes after the positive recommendation of the independent data safety monitoring board upon review of safety data from the first dose cohort.
  • The completed cohort also included the first subjects dosed with a sub-cutaneous formulation of zotatifin and preliminary analysis demonstrated equivalent plasma drug levels compared to IV delivery.
  • Achieving equivalent drug levels when zotatifin was delivered by the sub-cutaneous route provides an opportunity for convenient dosing in both the COVID and cancer settings.
  • As such, zotatifin may have a higher barrier to viral mutational escape than therapies that target components of the virus itself.

HOSP Expands Board, Adds Members And Partners

Retrieved on: 
Wednesday, June 8, 2022
General Health, Pharmaceutical, Health, Other Health, Association, Baystate Health, Board of directors, Director, UCSF School of Pharmacy, Record, Faculty of Pharmacy, University of Lisbon, Nebraska Medicine, Therapy, HOSP, UCSF School of Medicine, Industry, Board, Health system, Pharmacy and Therapeutics, Health, Hospital, Pharmacy

The Health System Owned Specialty Pharmacy Alliance ( HOSP ), the non-profit trade association dedicated to integrated specialty pharmacies, expanded its Board of Directors while accepting six new members and five partners to the organization last month.

Key Points: 
  • The Health System Owned Specialty Pharmacy Alliance ( HOSP ), the non-profit trade association dedicated to integrated specialty pharmacies, expanded its Board of Directors while accepting six new members and five partners to the organization last month.
  • Desi Kotis, Pharm.D FASHP, chief pharmacy executive, UCSF Health and associate dean and clinical professor, UCSF School of Pharmacy and Kyle Skiermont, vice president, Pharmacy and Therapeutics, Nebraska Medicine, College of Pharmacy University of Nebraska Medical Center, accepted seats on the Board of Directors increasing the Board total to 10 members.
  • Desi and Kyle bring vast industry expertise and long-standing successful track records in leadership positions to the Board in support of HOSPs mission, said Gary Kerr, President of the HOSP Board of Directors and Chief Pharmacy Officer at Baystate Health.
  • These new members and partners come from a variety of areas in the industry but are all focused on one thing: improving patient outcomes with integrated specialty pharmacies.

On Lok Announces Appointment of New Chief Medical Officer

Retrieved on: 
Monday, January 31, 2022
Infection, Leadership, San Francisco Department of Public Health, CEO, Patient, Dignity, Public health, SAN, American College, American College of Physicians, Program, San Francisco General Hospital, UCSF, CMO, Yale School of Medicine, UCSF School of Medicine, Technology, Intelligence, Research, Board, COVID-19, Meal, Internal medicine, Hospital, Health informatics, Informatics, PACE, Harvard University, SFGH, Case management, Quality assurance, California Health Care Foundation, Multimedia, Director, Medicine, Management, Lok, Physician

SAN FRANCISCO, Jan. 31, 2022 /PRNewswire/ -- On Lok has announced the appointment of Dr. Ben Lui as the organization's new Chief Medical Officer (CMO).

Key Points: 
  • SAN FRANCISCO, Jan. 31, 2022 /PRNewswire/ -- On Lok has announced the appointment of Dr. Ben Lui as the organization's new Chief Medical Officer (CMO).
  • Dr. Lui will also build upon the current clinical and medical care foundation at On Lok, adding his expertise in informatics and technology to further drive innovation in health care for older adults.
  • "Dr. Lui is an experienced and enthusiastic healthcare leader, dedicated to providing compassionate and innovative care to at-risk, underserved communities," said Grace Li, CEO of On Lok.
  • We look forward to his leadership in helping to shape the future of integrated medical and long-term support services for older adults through our work at On Lok."

DR. JEREMY DURACK AND DR. JOHN SIMPSON TO JOIN CORDIS-X INNOVATION ACCELERATOR

Retrieved on: 
Tuesday, January 18, 2022
Cardinal Health, Venous thrombosis, Hellman & Friedman, Patient, UCSF School of Medicine, Human, DVI, Stanford University School of Medicine, Interventional radiology, Ajax, University, Abbott, CA, Growth, EV3, CEO, Cardinal, American College of Cardiology, PTCA, Solution, Eli Lilly, Society of Interventional Radiology, Stanford University, History, Health, Duke University, Society, Cardiovascular disease, Thought, Memorial Sloan Kettering Cancer Center, Moses Austin, KKR, American College of Physicians, Doctor of Philosophy, MD, Boston Scientific, Physician, Clinical Genitourinary Cancer, Multimedia, American College, Radiology, Interventional oncology, Senior advisor, Medtech, ACS, Investment, Acquisition, Pharmaceutical industry, Medical imaging, Medtronic, Cordis, Medicine

"Recruiting Dr. John Simpson and Dr. Jeremy Durack, two of the greatest minds in cardiovascular science, will help us forge a bold new vision for Cordis."

Key Points: 
  • "Recruiting Dr. John Simpson and Dr. Jeremy Durack, two of the greatest minds in cardiovascular science, will help us forge a bold new vision for Cordis."
  • As Senior Advisor to Cordis-X, Dr. Simpson brings decades of scientific and commercial experience.
  • Dr. Jeremy Durack, an interventional radiologist and former Vice-Chair of Radiology at Memorial Sloan Kettering Cancer Center, will serve as Chief Clinical Officer for Cordis-X.
  • Cordis-X is an independent innovation accelerator with a streamlined go-to-market model built for speed, agility, and value maximization.

Medical Education Market to Grow by USD 143.30 billion | Harvard University and Johns Hopkins University Among Key Market Contributors | Technavio

Retrieved on: 
Saturday, January 15, 2022
Biomedical engineering, CAGR, Molecular biophysics, UCSF School of Medicine, Physiology, Harvard University, MEA, Biological illustration, Harvard Medical School, Johns Hopkins University, DNP, Growth, University of California, Biochemistry, Student, Stanford University, Genetic counseling, Genetics, HMX, USD, Health informatics, Geography, Infection, University, Pharmaceutical industry, Medicine, New York University, Science, Nursing, Epidemiology, Immunology, Medicine

NEW YORK, Jan. 14, 2022 /PRNewswire/ --The medical education market is expected to grow by USD 143.30 bn from 2020 to 2025.

Key Points: 
  • NEW YORK, Jan. 14, 2022 /PRNewswire/ --The medical education market is expected to grow by USD 143.30 bn from 2020 to 2025.
  • Request a Free Sample Report
    The growth in the number of online medical education programs is driving the growth of the medical education market.
  • Therefore, online medical education programs are becoming highly popular in the medical education market, which is expected to drive the growth of the market during the forecast period.
  • The presence of free and open-source education resources poses a significant threat to the growth of the medical education market.